EFFICACY OF PRAVASTATIN AND BEZAFIBRATE IN PRIMARY HYPERCHOLESTEROLEMIA

被引:9
作者
ARNTZ, HR
BONNER, G
KIKIS, D
KIRCH, W
KLOR, HU
LEDERLE, RM
OVERLACK, A
STEINMETZ, A
STUMPE, KO
机构
[1] UNIV COLOGNE,INNERE MED KLIN & POLIKLIN 2,W-5000 COLOGNE 41,GERMANY
[2] STADT KRANKENHAUS SOLINGEN,INNERE MED ABT,SOLINGEN,GERMANY
[3] UNIV KIEL,ALLGEMEINE INNERE MED ABT,W-2300 KIEL 1,GERMANY
[4] UNIV GIESSEN,MED POLIKLIN,W-6300 GIESSEN,GERMANY
[5] STADT KLINIKEN DORTMUND,MED KLIN 1,W-4600 DORTMUND,GERMANY
[6] UNIV BONN,MED POLIKLIN,W-5300 BONN,GERMANY
[7] UNIV MARBURG,ZENTRUM INNERE MED,W-3550 MARBURG,GERMANY
关键词
D O I
10.1055/s-2008-1063574
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The efficacy and safety of pravastatin and bezafibrate (in retard form) were compared in a randomised double-blind trial comprising 96 patients (48 men, 48 women; mean age 52.5 [20-68] years) with primary hypercholesterolaemia types IIa and IIb. After four weeks' treatment 6 out of 38 patients (400 mg/d bezafibrate) and 27 out of 58 patients (20 mg/d pravastatin) reached a LDL cholesterol level of 190 mg/dl or less. In the other 31 patients of the pravastatin group the dose was raised to 40 mg/d. During the twelve-week course of pravastatin total cholesterol concentration fell from a mean of 364 +/- 75 mg/dl (initial value) to 281 +/- 61 mg/dl (P < 0.01), while LDL-cholesterol fell from 288 +/- 81 mg/dl to 206 +/- 64 mg/dl (P < 0.01) and triglyceride concentration from 168 +/- 83 mg/dl to 148 +/- 80 mg/dl (P < 0.05). During the twelve-week course of treatment with 400 mg bezafibrate total cholesterol concentration fell from a mean of 363 +/- 91 mg/dl to 325 +/- 73 mg/dl (P < 0.01), LDL-cholesterol level fell from 284 +/- 88 mg/dl to 242 +/- 70 mg/dl (P < 0.01) and the triglyceride concentration from 173 +/- 91 mg/dl to 121 +/- 83 mg/dl (P < 0.01). HDL cholesterol concentration rose by 9% in the bezafibrate group and by 8.4% in the pravastatin group (P < 0.05). Except in the case of HDL-cholesterol, the falls were significantly different in the two treatment groups: pravastatin was superior to bezafibrate in terms of the reductions in both total and LDL-cholesterol (P < 0.01 for each). However, bezafibrate produced a greater fall in serum triglycerides (P < 0.05). No serious side effects were associated with either drug.
引用
收藏
页码:7 / 12
页数:6
相关论文
共 23 条
  • [1] BETTERIDGE DJ, 1989, NEW ADV CONTROL LIPI, P23
  • [2] CATALANO PM, 1989, NEW ADV CONTROL LIPI, P35
  • [3] DAYTON S, 1969, CIRCULATION S2, V40, P1
  • [4] CHEMISTRY, BIOCHEMISTRY, AND PHARMACOLOGY OF HMG-COA REDUCTASE INHIBITORS
    ENDO, A
    [J]. KLINISCHE WOCHENSCHRIFT, 1988, 66 (10): : 421 - 427
  • [5] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE
    FRICK, MH
    ELO, O
    HAAPA, K
    HEINONEN, OP
    HEINSALMI, P
    HELO, P
    HUTTUNEN, JK
    KAITANIEMI, P
    KOSKINEN, P
    MANNINEN, V
    MAENPAA, H
    MALKONEN, M
    MANTTARI, M
    NOROLA, S
    PASTERNACK, A
    PIKKARAINEN, J
    ROMO, M
    SJOBLOM, T
    NIKKILA, EA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) : 1237 - 1245
  • [6] FRIEDEWALD WT, 1972, CLIN CHEM, V8, P499
  • [7] GRUNDY SM, 1988, NEW ENGL J MED, V319, P24
  • [8] GRUTZMACHER P, 1981, P EUR DIAL TRANS, V18, P169
  • [9] ILLINGWORTH DR, 1987, AM J CARDIOL, V60, P33
  • [10] OSLO DIET-HEART STUDY - 11-YEAR REPORT
    LEREN, P
    [J]. CIRCULATION, 1970, 42 (05) : 935 - +